Acrux-Organon partnership dropped
Friday, 15 August, 2008
Acrux [ASX: ACR] has announced that projects it had been developing with Dutch pharma Organon have been cancelled after Organon's new owners Schering-Plough pulled the plug.
Acrux and Organon had been collaborating on a transdermal spray that was to add an undisclosed Organon proprietary drug to Acrux's contraceptive spray technology.
Acrux had already delivered on the first stage of the project, developing spray formulations for testing in clinical trials, and had been given $1 million in non-refundable payments on signing the collaboration agreement.
According to Acrux representatives, the decision has had no effect on the company's funding.
Acrux's own contraceptive spray development remains on track, with commercialisation expected to begin next year for several products.
Overuse of inhalers can increase heart attack risk
Overuse of reliever inhalers is associated with higher risks of developing and dying from...
Unhealthy Western diet could accelerate cognitive decline
An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
